Gilead Sciences Financials

Gilead Sciences Inc

GILDNASDAQ

Trade with Public

$156.19

-1.18-0.75%

Ult. Agg.: Oct 16, 6:55 PM

$156.84

-0.53-0.34%

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Dividendi Confronta Opzioni Rapporto azionario

Utili: I risultati di Q3 2026 tra 11 giorni da adesso in gio ott 29th, dopo la chiusura del mercato

Gilead Sciences Financials

Gilead Sciences (GILD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est

Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) analyst estimate..

Benzinga Newsdesk

PRO
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est

Gilead Sciences (NASDAQ:GILD) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) analyst estimate. Raises FY2026 sales outlook from $30.000 billion-$30.400 billion to $30.100

Benzinga Newsdesk

PRO
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

Gilead Sciences (NASDAQ:GILD) reported quarterly losses of $(6.75) per share which beat the analyst consensus estimate of $(7.24) by 6.64 percent. This is a 435.82 percent decrease over earnings of $2.01 per share from

Benzinga Newsdesk

PRO
Gilead Sciences Raises FY2026 Sales Guidance from $29.600B-$30.000B to $30.000B-$30.400B vs $30.216B Est

Guidance and OutlookFor the full year 2026, Gilead now expects:(in millions, except per share amounts) May 7, 2026 Guidance Comparison to February 10, 2026 Guidance Low EndHigh EndProduct

Benzinga Newsdesk

PRO
Gilead Sciences Lowers FY2026 Adj EPS Guidance from $8.45-$8.85 to $(1.05)-$(0.65) vs $8.66 Est

GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited) (in millions, except percentages and per share amounts) Provided February 10,

Benzinga Newsdesk

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $6.75-$7.15 to $(3.25)-$(2.85) vs $7.51 Est

GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited) (in millions, except percentages and per share amounts) Provided February 10,

Benzinga Newsdesk

Gilead Sciences Inc

Gilead Sciences Financials

Earnings & Guidance News

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est

PRO
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est

PRO
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

PRO
Gilead Sciences Raises FY2026 Sales Guidance from $29.600B-$30.000B to $30.000B-$30.400B vs $30.216B Est

PRO
Gilead Sciences Lowers FY2026 Adj EPS Guidance from $8.45-$8.85 to $(1.05)-$(0.65) vs $8.66 Est

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $6.75-$7.15 to $(3.25)-$(2.85) vs $7.51 Est

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Gilead Sciences Financials

Earnings & Guidance News

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est

PRO
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est

PRO
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

PRO
Gilead Sciences Raises FY2026 Sales Guidance from $29.600B-$30.000B to $30.000B-$30.400B vs $30.216B Est

PRO
Gilead Sciences Lowers FY2026 Adj EPS Guidance from $8.45-$8.85 to $(1.05)-$(0.65) vs $8.66 Est

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $6.75-$7.15 to $(3.25)-$(2.85) vs $7.51 Est

Gilead Sciences Inc

Gilead Sciences Financials

Earnings & Guidance News

PROGilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est

PROGilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est

PROGilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

PROGilead Sciences Raises FY2026 Sales Guidance from $29.600B-$30.000B to $30.000B-$30.400B vs $30.216B Est

PROGilead Sciences Lowers FY2026 Adj EPS Guidance from $8.45-$8.85 to $(1.05)-$(0.65) vs $8.66 Est

PROGilead Sciences Lowers FY2026 GAAP EPS Guidance from $6.75-$7.15 to $(3.25)-$(2.85) vs $7.51 Est

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Gilead Sciences Financials

Earnings & Guidance News

PROGilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est

PROGilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est

PROGilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

PROGilead Sciences Raises FY2026 Sales Guidance from $29.600B-$30.000B to $30.000B-$30.400B vs $30.216B Est

PROGilead Sciences Lowers FY2026 Adj EPS Guidance from $8.45-$8.85 to $(1.05)-$(0.65) vs $8.66 Est

PROGilead Sciences Lowers FY2026 GAAP EPS Guidance from $6.75-$7.15 to $(3.25)-$(2.85) vs $7.51 Est

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est

PRO
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est

PRO
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

PRO
Gilead Sciences Raises FY2026 Sales Guidance from $29.600B-$30.000B to $30.000B-$30.400B vs $30.216B Est

PRO
Gilead Sciences Lowers FY2026 Adj EPS Guidance from $8.45-$8.85 to $(1.05)-$(0.65) vs $8.66 Est

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $6.75-$7.15 to $(3.25)-$(2.85) vs $7.51 Est

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est

PRO
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est

PRO
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

PRO
Gilead Sciences Raises FY2026 Sales Guidance from $29.600B-$30.000B to $30.000B-$30.400B vs $30.216B Est

PRO
Gilead Sciences Lowers FY2026 Adj EPS Guidance from $8.45-$8.85 to $(1.05)-$(0.65) vs $8.66 Est

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $6.75-$7.15 to $(3.25)-$(2.85) vs $7.51 Est